No Detail Found!

The effects of dapagliflozin on the neovascularization of carotid atherosclerosis plaques in type 2 diabetes mellitus patients

Author(s)
Juanjuan Li Department of Endocrinology and Metabolism, Affiliated Hospital of Qingdao University,,China
Ying Xin Department of Endocrinology and Metabolism, Affiliated Hospital of Qingdao University,,China
Fang Wang Department of Endocrinology and Metabolism, Affiliated Hospital of Qingdao University,,China
Xiaoyun Dong Department of ultrasound, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University,,China
Lili Xu Department of Endocrinology and Metabolism, Affiliated Hospital of Qingdao University,,China
Abstract
This study investigated the effect of dapagliflozin on the neovascularization of carotid atherosclerotic plaques in patients with type 2 diabetes mellitus (T2DM) who failed to meet the initial treatment standard of metformin. Sixty patients with HbA1c 7.0-11.0% after metformin (2000 mg/day) treatment were included and randomized into two groups: group A (dapagliflozin) and group B (glimepiride). After 12 weeks of treatment, group A had lower mean blood glucose (MBG) and higher time in range (TIR) compared to group B. After 48 weeks of treatment, group A showed significant differences in various indicators compared to group B, including lower MBG, higher TIR, lower fasting insulin (FINS), improved insulin resistance, reduced systolic blood pressure (SBP), and lower BMI, waist-to-hip ratio (WHR) and time intensity curve of carotid angiography. No statistical differences in HbA1c, fasting blood glucose (FBG), diastolic blood pressure, low-density lipoprotein cholesterol (LDL), ALT, AST, blood urea nitrogen (BUN), serum creatinine or glomerular filtration rate (eGFR) after 12- and 48-week treatment between either group. Dapagliflozin treatment in T2DM patients can effectively control blood glucose, improve insulin resistance, reduce SBP, lower BMI and WHR, and improve the time intensity curve of carotid angiography, delaying the progress of diabetic macrovascular complications.
Publication Details
Page(s) 231-238
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 36, Issue: S1, Year: 2023

Request the full text from PASTIC

Keywords
type 2 diabetes, Dapagliflozin, Carotid atherosclerosis, macrovascular complications
0

Citations

0

Downloads

72

Views